Medpage Today on MSN5d
Hitting Psoriatic Arthritis Early With Apremilast Helps Some Patients, Trial Finds
With more than 300 patients in the trial, dubbed FOREMOST, 33.9% of those assigned to apremilast achieved minimal disease ...
Daily1d
FOREMOST Trial Reveals Apremilast Enhances Disease Control in Early Oligoarticular Psoriatic Arthritis
USA: The results of the FOREMOST trial indicate that apremilast is effective for patients with early psoriatic arthritis (PsA ...
Westside Current on MSN20h
TEPEZZA® (TEPROTUMUMAB) RECEIVES APPROVAL IN JAPAN FOR THE TREATMENT OF ACTIVE THYROID EYE DISEASE
Amgen (NASDAQ:AMGN) today announced TEPEZZA® (JAN: Teprotumumab (Genetical Recombination)) has been approved for the ...
stocknews22h
3 Biotech Stocks That Could Deliver Big Gains
The biotech industry is poised for significant growth, fueled by advanced technologies, the increased commercialization of ...
pharmaphorum4d
Otezla gains NICE approval for psoriatic arthritis
The Psoriatic Arthritis Long-t erm Assessment of Clinical Efficacy (PALACE) trial programme found Otezla to be superior to placebo but "compared with TNF-alpha inhibitors, apremilast was the ...
pharmaphorum2d
BMS scores first approval for psoriasis therapy Sotyktu
aiming to mount a challenge to Amgen's $2.3 billion oral psoriasis therapy Otezla (apremilast). BMS has previously said it reckons Sotyktu could become a $4 billion seller at its peak, fuelled by ...
The New York Times22h
New York Times - Top Stories
In U.N. Speech, Biden Says World Faces an ‘Inflection Point’ Amid Turmoil The U.N. General Assembly has begun in New York City as conflicts rage across the world. In his final U.N. speech ...
Reuters23h
United States
The U.S. Justice Department plans to charge the man accused of hiding with a gun at former President Donald Trump's Florida golf course with attempting to assassinate a major political candidate ...